Tomohiro Ozaki

922 total citations
19 papers, 188 citations indexed

About

Tomohiro Ozaki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Tomohiro Ozaki has authored 19 papers receiving a total of 188 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Tomohiro Ozaki's work include Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Tomohiro Ozaki is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Tomohiro Ozaki collaborates with scholars based in Japan and United States. Tomohiro Ozaki's co-authors include Kazuhiko Nakagawa, Isamu Okamoto, Masahiro Fukuoka, Kenji Tamura, Toshio Shimizu, Taroh Satoh, Koichi Azuma, Nobuyuki Yamamoto, Shogo Nomura and Yusaku Akashi and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Tomohiro Ozaki

19 papers receiving 185 citations

Peers

Countries citing papers authored by Tomohiro Ozaki

Since Specialization

Citations

This map shows the geographic impact of Tomohiro Ozaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomohiro Ozaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomohiro Ozaki more than expected).

Fields of papers citing papers by Tomohiro Ozaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomohiro Ozaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomohiro Ozaki. The network helps show where Tomohiro Ozaki may publish in the future.

Co-authorship network of co-authors of Tomohiro Ozaki

This figure shows the co-authorship network connecting the top 25 collaborators of Tomohiro Ozaki. A scholar is included among the top collaborators of Tomohiro Ozaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomohiro Ozaki. Tomohiro Ozaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single‐plex testing: WJOG13620L 2023 ·Cancer Medicine ·Takehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, Shunsuke Teraoka, (unknown), Koichi Azuma, Teppei Yamaguchi, Takeshi Masuda, Toshihide Yokoyama, Kohei Otsubo, Koji Haratani, Daisuke Hayakawa, (unknown), Shinnosuke Takemoto, Tomohiro Ozaki, Yusaku Akashi, Akito Hata, Hiroya Hashimoto, Nobuyuki Yamamoto, Kazuhiko Nakagawa	5
2	P29-1 LIGHT-NING: An observational study of nivolumab plus ipilimumab with or without chemotherapy for 1st line NSCLC in Japan 2022 ·Annals of Oncology ·Takashi Kijima, Koichi Azuma, Hidetoshi Hayashi, Koichi Nakatani, Tatsuro Fukuhara, Yukihiro Toi, Hisao Imai, Yasuto Yoneshima, (unknown), Tomohiro Ozaki, Satoru Kitazono, Naoki Ide, (unknown), Hidehito Horinouchi, Yuichiro Ohe	1
3	First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan 2022 ·JTO Clinical and Research Reports ·Yasushi Goto, Atsuhisa Tamura, Hirotaka Matsumoto, Kazutoshi Isobe, Tomohiro Ozaki, (unknown), K. Taniguchi, Tetsu Kamitani, (unknown), (unknown), (unknown), Thomas Burke, Hiroshi Nokihara	7
4	The safety and efficacy of durvalumab consolidation therapy in the management of patients with stage III non-small-cell lung cancer and preexisting interstitial lung disease 2022 ·Respiratory Investigation ·(unknown), Yuto Yasuda, Junko Tanizaki, (unknown), Yoshikane Nonagase, Kiyoshi Uemasu, Yutaka Hirayama, Masakazu Ogura, Tomohiro Ozaki, Kenichi Takahashi	6
5	Successful treatment with atezolizumab combination chemotherapy in a patient with high‐grade fetal adenocarcinoma of the lung: A case report 2022 ·Thoracic Cancer ·(unknown), Satomi Watanabe, Yuto Yasuda, (unknown), Yasuhiro Kawabata, (unknown), Takayuki Takahama, Kimio Yonesaka, Norishige Iizuka, Keníchi Takahashi, Osamu Kawakami, Tomohiro Ozaki, Kazuhiko Nakagawa	1
6	Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer 2021 ·European Journal of Cancer ·Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, Junko Tanizaki, Ryoji Kato, Seiichiro Mitani, (unknown), Takashi Kurosaki, Yoshikazu Hasegawa, Takafumi Okabe, Kaoru Tanaka, Yusaku Akashi, Tomohiro Ozaki, Kazuto Nishio, Akihiko Ito, Kazuhiko Nakagawa	10
7	Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer 2020 ·In Vivo ·Takashi Kurosaki, Hisato Kawakami, Seiichiro Mitani, Ryohei Kawabata, Takayuki Takahama, Yoshikane Nonagase, Soichi Fumita, Tomohiro Ozaki, Yasutaka Chiba, Takao Tamura, Kazuhiko Nakagawa	16
8	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer 2020 ·JAMA Oncology ·Isamu Okamoto, Hiroshi Nokihara, Shogo Nomura, Seiji Niho, Shunichi Sugawara, Hidehito Horinouchi, Koichi Azuma, Yasuto Yoneshima, Haruyasu Murakami, Yukio Hosomi, Shinji Atagi, Tomohiro Ozaki, Atsushi Horiike, Yuka Fujita, Hiroaki Okamoto, Masahiko Ando, Nobuyuki Yamamoto, Yuichiro Ohe, Kazuhiko Nakagawa	47
9	Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer 2020 ·The Oncologist ·Hidetoshi Hayashi, Masakazu Ogura, Takashi Niwa, Toshihide Yokoyama, Junko Tanizaki, Tomohiro Ozaki, Hiroshige Yoshioka, Takayasu Kurata, Yosuke Tamura, Yasuhito Fujisaka, Kaoru Tanaka, Yoshikazu Hasegawa, Keita Kudo, Yasutaka Chiba, Kazuhiko Nakagawa	3
10	Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L). 2019 ·Journal of Clinical Oncology ·Isamu Okamoto, Hiroshi Nokihara, Kiyotaka Yoh, Shunichi Sugawara, Hidehito Horinouchi, Koichi Azuma, Yasuto Yoneshima, Haruyasu Murakami, (unknown), Yukio Hosomi, Shinji Atagi, Tomohiro Ozaki, Atsushi Horiike, Yuka Fujita, Hiroaki Okamoto, Masahiko Ando, Shogo Nomura, Nobuyuki Yamamoto, Yuichiro Ohe, Kazuhiko Nakagawa	8
11	An experimental study on conducted noise emission for PMSM drive with SiC inverter: Conducted noise reduction by snubber circuit 2017 ·Tomohiro Ozaki, Tsuyoshi Funaki, (unknown)	2
12	Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity. 2014 ·PubMed ·Kimio Yonesaka, Tomohiro Suzumura, Hiroshi Tsukuda, Yoshikazu Hasegawa, Tomohiro Ozaki, (unknown), Masahiro Fukuoka	11
13	Adjuvant and neoadjuvant chemotherapy (NAC) with ifosfamide (IFO) and doxorubicin hydrochloride (ADM) for high-grade soft tissue sarcomas (STS) in the extremities: Japan Clinical Oncology Group study JCOG030404. 2011 ·Journal of Clinical Oncology ·(unknown), Junki Mizusawa, Hiroyuki Fukuda, Nobukazu Araki, (unknown), (unknown), Tomohiro Ozaki, Toru Hiruma, Haruyuki Tsuchiya, (unknown), (unknown), Tomoko Wada, (unknown), (unknown), Junya Toguchida, Sumiko Abe, Akihiko Matsumine, (unknown), Yuichiro Iwamoto	2
14	Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors 2009 ·Cancer Chemotherapy and Pharmacology ·Toshio Shimizu, Isamu Okamoto, Kenji Tamura, Taroh Satoh, Masaki Miyazaki, Yusaku Akashi, Tomohiro Ozaki, Masahiro Fukuoka, Kazuhiko Nakagawa	20
15	Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer 2009 ·European Journal of Cancer ·Kenji Tamura, Isamu Okamoto, Tomohiro Ozaki, Tatsuhiko Kashii, Koji Takeda, Masashi Kobayashi, Kaoru Matsui, Takashi Shibata, Takayasu Kurata, Kazuhiko Nakagawa, Masahiro Fukuoka	16
16	Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience 2007 ·International Journal of Clinical Oncology ·Toshio Shimizu, Taroh Satoh, Kenji Tamura, Tomohiro Ozaki, Isamu Okamoto, Masahiro Fukuoka, Kazuhiko Nakagawa	20
17	Epoetin Beta Subcutaneous Administration to Lung Cancer Patients with Anemia; Results of Pharmacokinetics/Pharmacodynamics Study 2007 ·Haigan ·Kazuhiko Nakagawa, Tomohiro Ozaki, Taroh Satoh, Masaki Miyazaki, Yusaku Akashi, Masaaki Terashima, Yasuhito Fujisaka, Tomohide Tamura, Masahiro Fukuoka, Nagahiro Saijo	2
18	Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. 2007 ·PubMed ·Tomohiro Ozaki, Kenji Tamura, Taroh Satoh, Takayasu Kurata, Toshio Shimizu, Masaki Miyazaki, Isamu Okamoto, Kazuhiko Nakagawa, Masahiro Fukuoka	1
19	Tumor Cyclooxygenase-2 Gene Suppresses Local Immune Responses in Patients with Hepatocellular Carcinoma 2006 ·Tumori Journal ·(unknown), Masahide Ikeguchi, (unknown), (unknown), Masashi Inoue, Tomohiro Ozaki, (unknown), (unknown), Kanenori Endo, Kuniyuki Katano, Yasuaki Hirooka	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact